Summary
Infectious disease outbreaks challenge societies by creating dynamic stochastic infection networks between human individuals in geospatial and demographical contexts. Minimizing human and socioeconomic costs of SARS-CoV-2 and future global pandemics requires data-driven and context-specific integrative modeling of detection-tracing, healthcare, and non-pharmaceutical interventions for decision-processes and reopening strategies. Traditional population-based epidemiological models cannot simulate temporal infection dynamics for individual human behavior in specific geolocations. We present an integrated geolocalized and demographically referenced spatio-temporal stochastic network- and agent-based model of COVID-19 dynamics for human encounters in real-world communities. Simulating intervention scenarios, we quantify effects of protection and identify the importance of early introduction of test-trace measures. Critically, we observe bimodality in SARS-CoV-2 infection dynamics so that the outcome of reopening can flip between good and poor outcomes stochastically. Furthermore, intervention effectiveness depends on strict execution and temporal control i.e. leaks can prevent successful outcomes. Schools are in many scenarios hubs for transmission, reopening scenarios are impacted by infection chain stochasticity and subsequent outbreaks do not always occur. This generalizable geospatial and individualized methodology is unique in precision and specificity compared to prior COVID-19 models [6, 16, 17, 19] and is applicable to scientifically guided decision processes for communities worldwide.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Deutsche Forschungsgemeinschaft (DFG: Cluster of Excellence MATH+, TRR 175) and by the German Ministry of Education and Research (BMBF, Liver Systems Medicine (LiSyM) network grant) and by the People Programme (Marie Skłodowska-Curie Actions) of the European Unions Horizon 2020 Programme under REA grant agreement no. 813979 (Secreters). Escalera-Fanjul X is supported with a postdoctoral grant from CONACYT (CVU 420248).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n.a.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code will be available shortly at https://tbp-klipp.science/GERDA/code/
